Latest & greatest articles for infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for infection

1. Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU

Recurrent uncomplicated urinary tract infections in women: AUA/CUA/SUFU Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019) - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular (...) Practice Resources Coding and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2019) Published 2019 [pdf] [pdf] Panel Members Jennifer Anger, MD, MPH; Una Lee, MD; A. Lenore Ackerman, MD, PhD; Roger Chou, MD; Bilal Chughtai, MD; J. Quentin Clemens, MD; Duane Hickling, MD, MSCI; Anil Kapoor, MD; Kimberly S. Kenton, MD, MS; Melissa R. Kaufman

2019 Canadian Urological Association

2. Curos for preventing infections when using needleless connectors

Curos for preventing infections when using needleless connectors Curos for pre Curos for prev venting infections when enting infections when using needleless connectors using needleless connectors Medical technologies guidance Published: 9 May 2019 www.nice.org.uk/guidance/mtg44 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility This guidance represents the view of NICE, arrived (...) . Curos for preventing infections when using needleless connectors (MTG44) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents Contents 1 Recommendations 4 2 The technology 6 3 Evidence 7 Clinical evidence 7 Cost evidence 8 4 Committee discussion 10 Clinical-effectiveness overview 10 NHS considerations overview 11 Cost modelling overview 12 Main cost drivers 12 Further research 12 5 Committee members

2019 National Institute for Health and Clinical Excellence - Medical technologies

3. The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs)

The Collaborative Assessment, OTCA12, on “C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections (RTIs) Dec2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged 1 EUnetHTA Joint Action 3 WP4 Version 1.4, +31 January 2019] Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment C-REACTIVE PROTEIN POINT-OF-CARE (...) TESTING (CRP POCT) TO GUIDE ANTIBIOTIC PRESCRIBING IN PRIMARY CARE SETTINGS FOR ACUTE RESPIRATORY TRACT INFECTIONS (RTIS) Project ID: OTCA012 C-reactive protein point-of-care testing to guide antibiotic prescribing for acute respiratory tract infections in primary care EUnetHTA Joint Action 3 WP4 2 DOCUMENT HISTORY AND CONTRIBUTORS Version Date Description V1.0 26/10/2018 First draft. V1.1 03/12/2018 Input from co-author has been processed. V1.2 03/12/2018 Input from dedicated reviewers has been

2019 EUnetHTA

4. A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection

A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection | The Ontario HIV Treatment Network The Ontario HIV Treatment Network A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection A cross-jurisdictional review of HIV testing intervals for population groups at high risk of HIV infection (...) , , , , , , , , , , Question At what intervals do high-income jurisdictions encourage population groups at high risk of HIV infection to come forward for routine testing? Key take-home messages Most guidelines recommend at least annual HIV testing of population groups at high risk of HIV infection. These include: men who have sex with men, transgender women and men, people who use injection drugs, African, Caribbean and Black communities, indigenous people, and women at risk. Some guidelines recommend more frequent

2019 Ontario HIV Treatment Network

5. Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection

Pre-emptive compared with empirical antifungal strategies for invasive Aspergillus infection SHTG Evidence Synthesis | 1 Evidence Synthesis Number 01 March 2019 Pre-emptive antifungal strategies incorporating galactomannan (GM) testing and/or polymerase chain reaction (PCR) assays compared with empirical antifungal strategies for invasive Aspergillus infection in patients with haematological malignancies What were we asked to look at? The Scottish Antimicrobial Prescribing Group (SAPG) asked us (...) to look at pre-emptive strategies incorporating galactomannan (GM) testing and/or polymerase chain reaction (PCR) assays compared with empirical antifungal treatment strategies for invasive Aspergillus infection in patients with haematological malignancies. Why is this important? Patients receiving treatments for haematological malignancies often experience severe and prolonged neutropenia which puts them at risk of life-threatening invasive fungal infections including Aspergillus infection. Since

2019 SHTG Advice Statements

6. Beta-D-glucan (BDG) tests for invasive Candida infection

Beta-D-glucan (BDG) tests for invasive Candida infection SHTG Advice Statement | 1 Advice Statement 02-19 January 2019 Advice Statement Clinical and cost effectiveness of diagnostic strategies incorporating Beta-D-glucan (BDG) tests to reduce unnecessary use of empirical antifungal therapies for invasive Candida infection in the critical care setting Advice for NHSScotland Overuse of empirical antifungal therapies in the critical care setting is a significant problem which exposes patients (...) is not fully offset by the savings realised from the reduction in antifungal use; SHTG Advice Statement | 2 ? The strategy is associated with a minimal incremental cost or is potentially cost- saving, in settings with higher testing throughputs (maximising test kit utilisation) and where there is low infection prevalence and high empirical use, and where micafungin or amphotericin B are the most commonly used agents; ? In units where use of empirical therapy is less common costs may be significantly

2019 SHTG Advice Statements

7. Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. (PubMed)

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients. Hearts and lungs from donors with hepatitis C viremia are typically not transplanted. The advent of direct-acting antiviral agents to treat hepatitis C virus (HCV) infection has raised the possibility of substantially increasing the donor organ pool by enabling the transplantation of hearts and lungs from HCV-infected donors into recipients who do not have HCV infection.We conducted a trial involving transplantation (...) of hearts and lungs from donors who had hepatitis C viremia, irrespective of HCV genotype, to adults without HCV infection. Sofosbuvir-velpatasvir, a pangenotypic direct-acting antiviral regimen, was preemptively administered to the organ recipients for 4 weeks, beginning within a few hours after transplantation, to block viral replication. The primary outcome was a composite of a sustained virologic response at 12 weeks after completion of antiviral therapy for HCV infection and graft survival at 6

2019 NEJM

8. Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries. (PubMed)

Community-based antibiotic delivery for possible serious bacterial infections in neonates in low- and middle-income countries. The recommended management for neonates with a possible serious bacterial infection (PSBI) is hospitalisation and treatment with intravenous antibiotics, such as ampicillin plus gentamicin. However, hospitalisation is often not feasible for neonates in low- and middle-income countries (LMICs). Therefore, alternative options for the management of neonatal PSBI in LMICs

2019 Cochrane

9. Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. (PubMed)

Association of HIV Preexposure Prophylaxis With Incidence of Sexually Transmitted Infections Among Individuals at High Risk of HIV Infection. Emerging evidence suggests that risk of bacterial sexually transmitted infections (STIs) increases among gay and bisexual men following initiation of HIV preexposure prophylaxis (PrEP).To describe STI incidence and behavioral risk factors among a cohort of predominantly gay and bisexual men who use PrEP, and to explore changes in STI incidence following

2019 JAMA

10. Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1)

Doravirine (Pifeltro) - for the treatment of adults infected with human immunodeficiency virus-1 (HIV-1) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

11. Diagnosis and Prevention of Periprosthetic Joint Infections

Diagnosis and Prevention of Periprosthetic Joint Infections 1 View the background material via the PJI CPG eAppendix 1 View data summaries via the PJI CPG eAppendix 2 DIAGNOSIS AND PREVENTION OF PERIPROSTHETIC JOINT INFECTIONS CLINICAL PRACTICE GUIDELINE Adopted by the American Academy of Orthopaedic Surgeons Board of Directors March 11, 2019 Please cite this guideline as: American Academy of Orthopaedic Surgeons. Diagnosis and Prevention of Periprosthetic Joint Infections Clinical Practice (...) Diagnosis 7 Diagnosis of Infected Joint Replacements 8 Diagnostic Imaging 9 Gram Stain 9 Avoiding antimicrobials two weeks prior to obtaining intra-articular culture to identify a pathogen for the diagnosis of PJI 9 Avoiding Initiating Antimicrobials prior to Obtaining Intra-Articular culture in patients suspected of having PJI 10 Antibiotics with low preoperative suspicion of PJI or established PJI with a known pathogen 10 Perioperative Antibiotic Selection 10 Antibiotic Cement 11 Preoperative

2019 American Academy of Orthopaedic Surgeons

12. Long-term antibiotics for preventing recurrent urinary tract infection in children. (PubMed)

Long-term antibiotics for preventing recurrent urinary tract infection in children. Urinary tract infection (UTI) is common in children. Symptoms include fever, lethargy, anorexia, and vomiting. UTI is caused by Escherichia coli in over 80% of cases and treatment is a course of antibiotics. Due to acute illness caused by UTI and the risk of pyelonephritis-induced permanent kidney damage, many children are given long-term (several months to 2 years) antibiotics aimed at preventing recurrence (...) ); detection bias (1); attrition bias (4); reporting bias (6); and other bias (1).Compared to placebo/no treatment, antibiotics lead to a modest decrease in the number of repeat symptomatic UTI in children; however the estimate from combining all studies was not certain and the confidence interval indicates low precision indicating that antibiotics may make little or no difference to risk of repeat infection (RR 0.75, 95% CI 0.28 to 1.98). When we combined only the data from studies with concealed

2019 Cochrane

13. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V

Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (HIV-infected children) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Elvitegravir/Cobicistat/Emtricitabin/Tenofovir- alafenamid (HIV-Infektion bei Kindern) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 12 April 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German (...) original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-01 Elvitegravir/cobicistat/ emtricitabine/tenofovir alafenamide (HIV-infected children) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-01 Version 1.0 EVG/COBI/FTC/TAF (HIV-infected children) 12 April 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

14. Surgical site infections: prevention and treatment

Surgical site infections: prevention and treatment Surgical site infections: pre Surgical site infections: prev vention and ention and treatment treatment NICE guideline Published: 11 April 2019 nice.org.uk/guidance/ng125 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Surgical site infections: prevention and treatment (NG125) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 27Contents Contents Overview 4 Who

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

15. Synovasure Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection

Synovasure Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection Synovasure® Alpha Defensin Lateral Flow Test Kit - Health Technology Wales > Synovasure® Alpha Defensin Lateral Flow Test Kit Synovasure® Alpha Defensin Lateral Flow Test Kit Topic Status Incomplete Synovasure ® Alpha Defensin Lateral Flow Test Kit for the assessment of periprosthetic joint infection. Summary Health Technology Wales researchers searched for evidence on whether the Synovasure (...) test can improve the diagnosis of periprosthetic joint infection. HTW’s Assessment Group concluded to progress this topic to Evidence Appraisal. The findings will be published as Evidence Appraisal Report EAR008. Please refer to this for the final agreed inclusion criteria for evidence. Topic Exploration Report TER015 (10.2018) TER Access our guidance Our advice documents are free to download, but we would be grateful if you could help us improve our services by telling us why you are looking

2019 Health Technology Wales

16. Tobramycin - treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis

Tobramycin - treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/886328/2018 EMEA/H/C (...) /005086 Tobramycin PARI (tobramycin) An overview of Tobramycin PARI and why it is authorised in the EU What is Tobramycin PARI and what is it used for? Tobramycin PARI is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis. Cystic fibrosis is an inherited disease in which thick mucus builds up in the lungs that allows bacteria to grow more easily, causing infections. P. aeruginosa

2019 European Medicines Agency - EPARs

17. Urological Infections

Urological Infections Urological Infections | Uroweb › Urological Infections Urological Infections To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . G. Bonkat (Chair), R.R. Bartoletti, F. Bruyère, T. Cai, S.E. Geerlings, B. Köves, S. Schubert, F. Wagenlehner Guidelines Associates: T. Mezei, A. Pilatz, B. Pradere, R. Veeratterapillay TABLE OF CONTENTS REFERENCES 1. Radmayr, C., et al. EAU (...) by Jeremy Howick March 2009. 1998. 5. Guyatt, G.H., et al. Going from evidence to recommendations. BMJ, 2008. 336: 1049. 6. Horan, T.C., et al. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control, 2008. 36: 309. 7. Rubin, R.H., et al. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration

2019 European Association of Urology

18. Pregnancy and lower urinary tract infection: opt for cefuroxime

Pregnancy and lower urinary tract infection: opt for cefuroxime Prescrire IN ENGLISH - Spotlight ''Pregnancy and lower urinary tract infection: opt for cefuroxime'', 1 April 2019 {1} {1} {1} | | > > > Pregnancy and lower urinary tract infection: opt for cefuroxime Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregnancy and lower urinary tract (...) infection: opt for cefuroxime Requiring just a single dose, fosfomycin trometamol is easier to take than cefuroxime or the combination of amoxicillin + clavulanic acid, but less is known about its short-term effects on the unborn child exposed during the first trimester of pregnancy. It is wiser to choose cefuroxime as first-line treatment. Minor lower urinary tract infections are frequent during pregnancy. They are routinely treated because they are a risk factor for premature birth. The first-choice

2019 Prescrire

19. Influenza infection

Influenza infection Influenza infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Influenza infection Last reviewed: February 2019 Last updated: March 2019 Summary Characterised by upper and lower respiratory tract symptoms of rhinorrhoea, cough, fever, chills, headache, and myalgia. Typically presents in winter season. Can occur in local community outbreaks, epidemics, and, rarely, pandemics. Vaccination (...) for prevention is available. Definition Acute respiratory tract infection typically caused by seasonal influenza A or B virus. The virus is transmitted by inhalation of infected respiratory secretions that have been aerosolised through coughing, sneezing, or talking. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7:257-265. http://www.ncbi.nlm.nih.gov/pubmed/17376383?tool=bestpractice.com History and exam winter season current influenza outbreak

2019 BMJ Best Practice

20. Poliovirus infection

Poliovirus infection Poliovirus infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Poliovirus infection Last reviewed: February 2019 Last updated: March 2019 Summary Usually asymptomatic. When symptomatic, the most common presentation is a minor gastrointestinal illness. Acute flaccid paralysis (AFP), or paralytic poliomyelitis, is the hallmark of the major illness. A minority of affected cases with AFP (...) progress to life-threatening bulbar paralysis and respiratory compromise. Post-poliomyelitis syndrome may occur many years after the initial illness, and consists of weakness and fatigue in muscle groups previously affected in the acute illness. There is no cure for poliovirus infection or post-poliomyelitis syndrome, and treatment is mainly supportive. Early physiotherapy is key to maximising and restoring limb function in paralytic poliomyelitis and in post-poliomyelitis syndrome. The cornerstones

2019 BMJ Best Practice